Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by subaru1ion Apr 04, 2024 11:11am
117 Views
Post# 35970417

LABS research partner, McMaster to host 'infectious disease'

LABS research partner, McMaster to host 'infectious disease'conference, that would include viruses like avian bird flu, and at DeGroote School of Medicine where research work on the anti viral, anti bacterial, antibiotic properties of cannabinoid pharmaceuticals was conducted.   Mr. Pidduck, you do not have yet true 'global capacity' relative to emerging demand within the realm of viruses.   Time is running out and running out very quickly.   For an intelligent species, I have to admit, humans make things so complicated and cumbersome.   A price paid for coveting the light that nurtures those cannabis plants but so too that light contains the Truth π and those amongst us that want to have 'their piece of cake and eat it too', just like monkeys,  that hide the Truth π of Life π within the nuclear fusion atmosphere of the Sun π.   Pentagon/NSA...enjoy your cake now and make sure you eat every bite. 

“Having more people in Canada who are trained in these areas will allow us to respond quickly to emerging infectious disease outbreaks, and to do so in a data-driven way,” says McArthur, a member of the Michael G. DeGroote Institute for Infectious Disease Research 


Technical Update: Summary Analysis of Genetic Sequences of Highly Pathogenic Avian Influenza A(H5N1) Viruses in Texas

April 2, 2024 – CDC has sequenced the influenza virus genome identified in a specimen collected from the patient in Texas who was confirmed to be infected with highly pathogenic avian influenza A(H5N1) [“HPAI A(H5N1)”] virus 
<< Previous
Bullboard Posts
Next >>